Search Within

Martin Stuart Tallman

Formats
  1. Journal Article (321)
  2. Meeting Abstract (280)
  3. Review (19)
  4. Editorial (10)
  5. Book Section (8)
  6. Research Letter (8)
  7. Guidelines (6)
  8. Correspondence (1)
Groups
  1. Adult Leukemia (653)
  2. Center for Hematologic Malignancies (653)
  3. Department of Medicine (653)
  4. Hematologic Malignancies, Division of (653)
  5. GSK Faculty (164)
  6. Executive Committee, Center for Hematologic Malignancies (156)

More Groups

People
  1. Ross Levine (131)
  2. Eytan Stein (116)
  3. Jae Park (80)
  4. Omar Abdel-Wahab (68)
  5. Sean Devlin (65)
  6. Dan Douer (50)

More People

Years
  1. 2025 (5)
  2. 2024 (9)
  3. 2023 (10)
  4. 2022 (26)
  5. 2021 (45)
  6. 2020 (51)

More Years

Publications
  1. Blood (274)
  2. Journal of Clinical Oncology (41)
  3. Blood Advances (27)
  4. Leukemia Research (27)
  5. Leukemia and Lymphoma (26)
  6. Haematologica (25)

More Publications

Publishers
  1. American Society of Hematology (301)
  2. Elsevier Inc. (43)
  3. American Society of Clinical Oncology (41)
  4. Nature Publishing Group (38)
  5. Taylor & Francis Group (28)
  6. Elsevier Ltd (27)

More Publishers

Results (653)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • High dose daunorubicin improves survival in AML up to age 60, across all cytogenetic Risk groups including patients with unfavorable cytogenetic risk, and FLT3-ITD mutant AML: Updated analyses from Eastern Cooperative Oncology trial E1900
    Meeting Abstract

    Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Results of the ECOG E1900 trial in younger adults with AML using an event free survival endpoint are concordant with results based on overall survival: Potential for a surrogate endpoint to facilitate rapid approval of therapies in AML
    Meeting Abstract

    Luskin, M. R.; Lee, J. W.; Fernandez, H. F.; Lazarus, H. M.; Rowe, J. M.; Tallman, M. S.; Paietta, E. M.; Litzow, M.; Abdel-Wahab, O.; Patel, J. P.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • A randomized phase II trial of three novel regimens for relapsed/refractory acute myeloid leukemia (AML) demonstrates encouraging results with a flavopiridol-based regimen: Results of Eastern Cooperative Oncology Group (ECOG) trial E1906
    Meeting Abstract

    Litzow, M. R.; Wang, X. V.; Carroll, M. P.; Karp, J. E.; Ketterling, R.; Kaufmann, S. H.; Lazarus, H. M.; Luger, S. M.; Paietta, E. M.; Rowe, J. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Genomic analysis of serial samples from CLL patients identifies clonal events associated with disease progression
    Meeting Abstract

    Gardner, J. R.; Nahas, M.; He, J.; Aumann, S.; Gonen, M.; Patel, M.; Knapp, K. M.; Palomba, M. L.; Yelensky, R.; Donahue, A. L.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Minimal residual disease assessment by flow cytometry in AML is an independant prognostic factor even after adjusting for cytogenetic/molecular abnormalities
    Meeting Abstract

    Ganzel, C.; Sun, Z. X.; Gonen, M.; Patel, J. P.; Abdel-Wahab, O.; Fernandez, H. F.; Rowe, J. M.; Tallman, M. S.; Levine, R. L.; Paietta, E. M.
    Blood (2014)

    Fulltext@MSK | Save
  • Secondary ALL may be independent of prior cytotoxic therapy
    Meeting Abstract

    Ganzel, C.; Devlin, S. M.; Douer, D.; Stein, E. M.; Rowe, J. M.; Tallman, M. S.
    Blood (2014)

    Fulltext@MSK | Save
  • The addition of radiation therapy to initial treatment for extramedullary acute myeloid leukemia does not offer a survival benefit when added to chemotherapy
    Meeting Abstract

    Feller, F. M.; Patel, M.; Devlin, S. M.; Maloy, M.; Tallman, M. S.; Perales, M. A.; Rampal, R. K.
    Blood (2014)

    Fulltext@MSK | Save
  • Utility of combined DNA and RNA next generation sequencing in leukemias for identification of prognostic and therapeutically relevant genomic alterations in clinical practice
    Meeting Abstract

    Coombs, C. C.; Viny, A. D.; He, J.; Kobos, R.; Lipson, D.; Shukla, N.; Knapp, K. M.; Otto, G.; Abdel-Wahab, O.; Stein, E. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • Hyperactive PTPN11 mutations alters leukemic stem cell frequency through Mcl-1 overexpression
    Meeting Abstract

    Chen, L. L.; Chen, W.; Mysliwski, M.; Serio, J.; Ropa, J.; Abulwerdi, F.; Chan, R. J.; Patel, J. P.; Tallman, M. S.; Paietta, E. M.; more...
    Blood (2014)

    Fulltext@MSK | Save
  • BL-8040, a peptidic CXCR4 antagonist, induces leukemia cell death and specific leukemia cell mobilization in relapsed/refractory acute myeloid leukemia patients in an ongoing phase IIA clinical trial
    Meeting Abstract

    Borthakur, G.; Nagler, A.; Ofran, Y.; Rowe, J. M.; Altman, J. K.; Frankfurt, O.; Tallman, M. S.; Avivi, I.; Peled, A.; Pereg, Y.; more...
    Blood (2014)

    Fulltext@MSK | Save